We are live on ! Find out more
SGYP

Synergy Pharmaceuticals, Inc Common Stock
SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

129 hedge funds and large institutions have $343M invested in Synergy Pharmaceuticals, Inc Common Stock in 2015 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 51 increasing their positions, 36 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 36

37% more call options, than puts

Call options by funds: $5.57M | Put options by funds: $4.08M

29% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 24

5% more funds holding

Funds holding: 123129 (+6)

20% less capital invested

Capital invested by funds: $431M → $343M (-$88M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
129
Holders Change
+6
Holders Change %
+4.88%
% of All Funds
3.6%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
31
Increased
51
Reduced
36
Closed
24
Calls
$5.57M
Puts
$4.08M
Net Calls
+$1.5M
Net Calls Change
-$347K
Name Holding Trade Value Shares
Change
Change in
Stake
PC
1
Paulson & Co
New York
$47.7M +$24.9M +3,218,500 +56%
Vanguard Group
2
Vanguard Group
Pennsylvania
$34.3M +$7.19M +929,568 +17%
BFA
3
BlackRock Fund Advisors
California
$29.3M +$12.3M +1,588,633 +40%
State Street
4
State Street
Massachusetts
$27.1M +$25.8M +3,337,407 +189%
Citadel Advisors
5
Citadel Advisors
Florida
$20.7M +$25.8M +3,327,408 +567%
Millennium Management
6
Millennium Management
New York
$14.3M +$2.92M +377,257 +16%
BIT
7
BlackRock Institutional Trust
California
$13.2M +$3.73M +482,415 +24%
O
8
OrbiMed
New York
$12.1M -$6.54M -844,500 -27%
Invesco
9
Invesco
Georgia
$11.2M -$2.54M -328,021 -13%
Franklin Resources
10
Franklin Resources
California
$10.8M +$524K +67,767 +3%
JP Morgan Chase
11
JP Morgan Chase
New York
$6.12M +$6.43M +830,625 +256%
GPP
12
Great Point Partners
Connecticut
$6.02M -$6.77M -874,404 -44%
Northern Trust
13
Northern Trust
Illinois
$5.66M +$233K +30,044 +3%
Deutsche Bank
14
Deutsche Bank
Germany
$5.19M +$6.99M +902,736 +1,182%
TCP
15
Tourbillon Capital Partners
New York
$5.16M +$3.91M +504,937 +108%
Lord, Abbett & Co
16
Lord, Abbett & Co
New Jersey
$4.68M -$1M -129,642 -13%
Allianz Asset Management
17
Allianz Asset Management
Germany
$4.67M +$4.99M +644,975 +272%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$4.57M +$76.4K +9,871 +1%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$3.46M +$532K +68,735 +12%
UBS AM
20
UBS AM
Illinois
$3.37M -$29.4K -3,800 -0.6%
Citigroup
21
Citigroup
New York
$3.24M +$4.61M +595,103 +3,606%
GTC
22
Ghost Tree Capital
New York
$3.18M +$4.64M +600,000 New
DCM
23
Driehaus Capital Management
Illinois
$3.16M +$370K +47,793 +9%
PC
24
PointState Capital
New York
$3M +$4.38M +566,192 New
NIP
25
Nicholas Investment Partners
California
$2.79M +$2.64M +341,399 +184%

SGYP Hedge Fund Activity: Q3 2015 in Review

129 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q3 2015, worth a combined $343M — down 20% from $431M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new SGYP positions and 24 closed out — a net gain of 7 holders — while 51 added to existing stakes and 36 trimmed.

The largest buyer was State Street, adding an estimated $25.8M. The largest seller was York Capital Management Global Advisors, exiting entirely with an estimated $15.4M sold.

  • 129 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q3 2015, up from 123 in Q2 2015.
  • Funds reported $343M of Synergy Pharmaceuticals, Inc Common Stock stock for Q3 2015, down 20% quarter-over-quarter.
  • 31 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q3 2015 and 24 closed out, a net change of +7 holders.
  • The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q3 2015 was State Street, an estimated $25.8M added.
  • The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q3 2015 was York Capital Management Global Advisors, an estimated $15.4M sold.

Based on aggregated 13F filings for Q3 2015.